Regeneron Pharmaceuticals and Bayer HealthCare have initiated a Phase III study of the VEGF Trap-Eye for the treatment of wet age-related macular degeneration (AMD).
Regeneron Pharmaceuticals and Bayer HealthCare have initiated a Phase III study of the VEGF Trap-Eye for the treatment of wet age-related macular degeneration (AMD).
The trial, known as VIEW 1 (VEGF Trap: Investigation of Efficacy and safety in Wet age-related macular degeneration) will be a non-inferiority comparison of the VEGF Trap-Eye and ranibizumab (Lucentis; Novartis).
The randomized, double-masked Phase III study is aiming to enrol approximately 1,200 patients at more than 200 centres across the US and Canada. It will evaluate the drug's efficacy and safety at doses of 0.5 mg and 2.0 mg administered at four-week intervals and 2.0 mg at eight-week intervals, compared with 0.5 mg of ranibizumab administered every four-weeks.
The primary endpoint will be the proportion of patients who maintain or improve vision at the end of one year, compared with ranibizumab patients.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.